A number of stocks fell in the afternoon session after investors raised concerns over the stability of the private credit market, following a key announcement from a major bank.

Mohamad Makhzoumi, a ten percent owner of Korro Bio, Inc. (NASDAQ:KRRO), has purchased 207,100 shares of common stock at a price of $11.11, for a total value of $2,300,881. The purchase comes as the ...

Earnings call Nektar ended 2025 with $245.8M in cash and no debt, bolstered by an additional $476M in early 2026. REZPEG advanced to phase 3 in atopic dermatitis with phase 3 initiation set for June ...

Piper Sandler also upgraded Korro Bio to Overweight, significantly increasing its price target to $30.00, following the introduction of KRRO-121 for Urea Cycle Disorders and Hepatic Encephalopathy.

Earnings call Health Catalyst reported Q4 2025 revenue of $74.7M (down YoY), with full-year revenue up 1% to $311.1M and Adjusted EBITDA up 59% to $41.4M. Despite strong cost control and margin gains, ...